Back

Therapeutic effects of human amnion-derived mesenchymal stem cells on hypercoagulability in a uremic calciphylaxis patient

Bian, A.; Ye, X.; Wang, J.; Zeng, M.; Liu, J.; Liu, K.; Ning, S.; Cui, Y.; Tang, S.; Xu, X.; Yuan, Y.; Su, Z.; Lu, Y.; Zhou, J.; Ma, X.; Yang, G.; Huang, Y.; Lv, X.; Wang, L.; Zhao, J.; Wang, X.; Liang, N.; Xing, C.; Qin, L.; Wang, N.

2023-01-07 nephrology
10.1101/2023.01.06.22283161 medRxiv
Show abstract

Calciphylaxis is a rare cutaneous vascular disease with clinical manifestations of intolerable pains, non-healing skin wounds, histologically characterized by calcification, fibrointimal hyperplasia, and thrombosis in microvessels. Currently, there are no approved guidelines for this disease. High prevalence of thrombophilias and hypercoagulable conditions in calciphylaxis patients have been recognized in recent years. Here, we report a case of uremic calciphylaxis patient whom was refractory to conventional treatments and then received a salvage strategy via human amnion-derived mesenchymal stem cell (hAMSC) intravenous combined with local application. In order to investigate the therapeutic mechanism of hMASCs from the novel perspective of hypercoagulability, coagulation-related indicators, wound status and quality of life were followed up. Improvement of hypercoagulable condition involving correction of platelet, D-dimer and plasminogen levels, skin regeneration and pain alleviation were revealed after hAMSC administration for one year. We propose that hypercoagulability is the therapeutic target of calciphylaxis patients which can be improved by hAMSC treatment.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.